Sponsor	Phase
Vertex Pharmaceuticals Incorporated	PHASE1
Benha University	Phase 2/Phase 3
Amgen	Phase 1

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Womens	PREFEST	estradiol; norgestimate	TABLET;ORAL	021040-001	Oct 22, 1999		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Barr	ESTRADIOL AND NORGESTIMATE	estradiol; norgestimate	TABLET;ORAL	076812-001	Apr 29, 2005		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva Womens	PREFEST	estradiol; norgestimate	TABLET;ORAL	021040-001	Oct 22, 1999	⤷ Start Trial	⤷ Start Trial
Teva Womens	PREFEST	estradiol; norgestimate	TABLET;ORAL	021040-001	Oct 22, 1999	⤷ Start Trial	⤷ Start Trial
Teva Womens	PREFEST	estradiol; norgestimate	TABLET;ORAL	021040-001	Oct 22, 1999	⤷ Start Trial	⤷ Start Trial
Teva Womens	PREFEST	estradiol; norgestimate	TABLET;ORAL	021040-001	Oct 22, 1999	⤷ Start Trial	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Last updated: September 3, 2026

The estradiol/norgestimate market is a legacy menopausal hormone-therapy segment with limited current commercial relevance. The combination was marketed in the United States as Prefest, a sequential oral regimen containing estradiol and norgestimate. Its commercial position weakened as generic estrogen products, transdermal delivery, lower-dose regimens, and newer menopause therapies gained share. No meaningful current product-level revenue is publicly reported, and the U.S. product no longer has an active exclusivity profile comparable to newer branded hormone therapies.

Estradiol/Norgestimate Market Dynamics, Patent Status, and Financial Trajectory

What is estradiol/norgestimate and which product contained it?

Estradiol/norgestimate is an oral estrogen-progestin combination used for menopausal hormone therapy. Estradiol supplies systemic estrogen replacement, while norgestimate provides progestogenic activity intended to reduce the risk of endometrial hyperplasia associated with unopposed estrogen in women with an intact uterus.

The principal U.S. branded product was Prefest. It used a sequential regimen that combined estradiol-only tablets with tablets containing estradiol and norgestimate. The product was developed for vasomotor symptoms and other estrogen-deficiency indications associated with menopause.

Attribute	Estradiol/norgestimate
Active ingredients	Estradiol and norgestimate
Therapeutic category	Menopausal hormone therapy
Dosage form	Oral tablet
Historical U.S. brand	Prefest
Estrogen dose	Commonly marketed as estradiol 1 mg
Progestin dose	Commonly marketed as norgestimate 0.09 mg
Primary use	Menopausal vasomotor and estrogen-deficiency symptoms
Regulatory status	Historically FDA-approved; commercial availability has materially declined
Biosimilar exposure	None
Current commercial profile	Legacy or discontinued-product economics

The product differs from combined oral contraceptives containing ethinyl estradiol and norgestimate. Menopausal hormone therapy uses estradiol, generally at lower estrogen exposure than contraceptive regimens, and has a different risk-benefit framework.

How large is the estradiol/norgestimate market?

The current market for estradiol/norgestimate is small relative to the overall menopause hormone-therapy market. Public company filings generally do not disclose revenue for Prefest or for estradiol/norgestimate as a separate product line. The lack of product-level sales reporting indicates that the combination is not a material revenue driver for a large public pharmaceutical company.

Market demand has shifted toward several alternatives:

Generic oral estradiol products.
Generic conjugated estrogens and progestin combinations.
Transdermal estradiol patches, gels, and sprays.
Oral estradiol combined with micronized progesterone.
Lower-dose continuous-combination products.
Nonhormonal therapies for vasomotor symptoms.

The combination also competes against products with more familiar prescribing patterns. Activella, containing estradiol and norethindrone acetate, has had a larger commercial footprint in the U.S. menopausal hormone-therapy market. Bijuva, containing estradiol and micronized progesterone, targets patients and prescribers seeking a combination using body-identical hormones. Transdermal estradiol products compete on perceived cardiovascular and metabolic advantages in selected patients, although clinical suitability depends on individual risk factors.

When did estradiol/norgestimate lose exclusivity?

Estradiol/norgestimate no longer has commercially meaningful regulatory exclusivity in the United States. Any original new-drug exclusivity and patent protection associated with Prefest expired years ago or ceased to protect an active commercial franchise.

The product's competitive protection was limited because:

The active ingredients are established molecules.
The dosage form is a conventional oral tablet.
Menopausal hormone therapy has a mature generic market.
The product did not create a durable delivery-system barrier.
Physicians could substitute clinically familiar estrogen and progestin regimens.

FDA regulatory exclusivity is distinct from patent protection. New chemical entity exclusivity would not be expected for a combination using previously known estradiol and norgestimate. Any protection would have depended on combination, formulation, manufacturing, or method-of-use claims rather than new-molecule exclusivity.

What patents protect estradiol/norgestimate?

The principal historical protection would have centered on the combination product, its sequential dosing architecture, and pharmaceutical formulation. No current high-value patent estate is publicly associated with estradiol/norgestimate comparable to the patent portfolios supporting newer long-acting injectables, complex generics, or biologics.

Patent category	Strategic relevance for estradiol/norgestimate	Current commercial significance
Active-ingredient patents	Low; estradiol and norgestimate are old molecules	None expected
Combination patents	Could cover estrogen-progestin pairing or ratios	Historical relevance
Regimen patents	Could cover sequential or cyclic administration	Limited after expiration
Formulation patents	Could cover tablet composition or release profile	Limited barrier for conventional tablets
Manufacturing patents	Could cover tableting, granulation, or dosage uniformity	Usually narrow and difficult to monetize
Method-of-use patents	Could cover menopausal symptom treatment	Weak if broad generic substitution remains available
Delivery-system patents	Not a major feature of the product	No meaningful current barrier

The main patent risk for a generic entrant would have been claim construction around the specific sequential regimen rather than the active ingredients themselves. A conventional generic containing the same active ingredients might still have required a regulatory strategy addressing formulation, labeling, and any listed patents.

What is the Orange Book status of estradiol/norgestimate?

The Orange Book is relevant because it identifies approved drug products, therapeutic-equivalence evaluations, patent listings, and regulatory exclusivity. The historical Prefest listing is no longer the type of active, commercially significant reference listed drug that creates a substantial market barrier.

An FDA designation of a product as discontinued does not, by itself, mean that FDA withdrew the product for safety or efficacy reasons. It generally reflects commercial discontinuation or the sponsor's decision to stop marketing. FDA product records and the Orange Book must be distinguished from safety communications and formal withdrawal actions. [1]

The absence of a currently active branded product creates a practical issue for generic development: a generic applicant may need to establish a viable reference-product pathway and demonstrate that the regulatory route remains available for the intended formulation and labeling. The absence of active brand sales can reduce commercial incentive even where technical approval is feasible.

Were there Paragraph IV challenges to estradiol/norgestimate?

Publicly visible Paragraph IV activity has not created a material current market narrative for estradiol/norgestimate. The product's age and limited commercial value reduced the incentive for major generic manufacturers to pursue a high-cost patent challenge.

A Paragraph IV filing would have required a generic applicant to certify that a listed patent was invalid, unenforceable, or would not be infringed. For a legacy combination product, the economics would depend on:

Size of the remaining branded market.
Availability of a reference listed drug.
Number of active Orange Book patents.
Complexity of the sequential tablet regimen.
Expected first-filer exclusivity.
Reimbursement pricing after generic launch.

The likely commercial outcome would have been rapid price erosion rather than a sustained branded-generic contest. No major ongoing litigation involving estradiol/norgestimate is a recognized driver of the current menopause market.

What formulations are protected by estradiol/norgestimate patents?

The formulation concept was a conventional oral, sequential combination. Potential formulation claims could have addressed:

Estradiol-only and estradiol/norgestimate tablets packaged in a defined sequence.
Specific tablet strengths.
Excipients and dissolution characteristics.
Content uniformity for low-dose norgestimate.
Calendar packaging and dosing instructions.
Stability during storage.

These claims generally provide less durable protection than extended-release systems, transdermal matrices, implantable devices, or depot formulations. A competitor could also approach the same clinical objective with a different product, such as oral estradiol plus separate progesterone, avoiding direct duplication of the branded package.

How does estradiol/norgestimate compare with competing menopause therapies?

Product or approach	Estrogen	Progestogen	Delivery	Competitive position
Estradiol/norgestimate	Estradiol	Norgestimate	Oral sequential tablet	Legacy combination
Estradiol/norethindrone	Estradiol	Norethindrone acetate	Oral continuous combination	More established generic competition
Estradiol/micronized progesterone	Estradiol	Micronized progesterone	Oral capsule	Stronger “body-identical” positioning
Transdermal estradiol plus progesterone	Estradiol	Separate progesterone	Patch, gel, or spray plus oral therapy	Competes on route and dosing flexibility
Conjugated estrogens plus medroxyprogesterone	Conjugated estrogens	Medroxyprogesterone acetate	Oral	Older but familiar regimen
Local vaginal estrogen	Low-dose estradiol or other estrogen	Usually none	Vaginal	Targets genitourinary symptoms rather than systemic symptoms
Nonhormonal therapies	None	None	Oral or other	Relevant for women avoiding hormone therapy

Estradiol/norgestimate has no obvious differentiated delivery technology. Its principal differentiation was the dosing architecture and the use of norgestimate as the progestin. That distinction was insufficient to create a durable premium after generic estrogen and progestin alternatives became widely available.

What FDA regulatory issues affect the product?

The FDA's position on menopausal hormone therapy has been shaped by evidence from the Women's Health Initiative and subsequent analyses. Hormone therapy carries age-, dose-, duration-, route-, and patient-specific risks. FDA labeling emphasizes individualized treatment, periodic reassessment, and use of the lowest effective dose for the shortest appropriate duration. [2]

The regulatory environment affects commercial demand in four ways:

Prescribers evaluate systemic hormone therapy more selectively than before the broad dissemination of WHI findings.
Patients may prefer transdermal or local products depending on symptoms and risk profile.
Generic substitution reduces the value of a legacy brand.
Long-term treatment duration is constrained by individualized risk-benefit assessment.

The product's FDA history should not be confused with a safety withdrawal. Its commercial decline is better explained by market maturity, generic competition, changing prescribing behavior, and the availability of alternative hormone-therapy regimens.

Which companies are challenging estradiol/norgestimate?

No major current company challenge has materially altered the commercial position of estradiol/norgestimate. The competitive pressure has come from manufacturers of alternative products rather than from a sustained litigation campaign against an active branded franchise.

Relevant competitor groups include:

Generic manufacturers of oral estradiol.
Manufacturers of estradiol/norethindrone combinations.
Producers of transdermal estradiol.
Companies selling micronized progesterone.
Developers of nonhormonal vasomotor-symptom therapies.
Compounding pharmacies, which may supply customized hormone regimens but do not provide FDA-approved generic substitution.

The most important competitive threat is therapeutic substitution. A patient does not need a direct estradiol/norgestimate generic to leave the franchise. A physician can prescribe estradiol with a separate progestogen or use a different approved combination.

What is the financial trajectory for estradiol/norgestimate?

The financial trajectory is consistent with a late-life pharmaceutical product:

Period	Financial condition
Launch and early commercialization	Differentiated oral menopausal hormone-therapy product with brand pricing
Mature brand period	Pressure from established estrogen and progestin alternatives
Post-exclusivity period	Lower pricing and limited generic or therapeutic differentiation
Current market phase	Minimal reported revenue and limited strategic value

Revenue exposure for the original sponsor is likely immaterial today. Large pharmaceutical companies typically aggregate mature products into broader established-products or international categories rather than disclose individual sales. The absence of separately reported revenue is itself commercially relevant: the product is unlikely to influence corporate guidance, valuation, or licensing strategy.

A buyer would face a weak investment case unless the asset were bundled with a broader women's-health portfolio. Standalone acquisition value would be constrained by:

Limited brand recognition.
Lack of active exclusivity.
Low switching costs.
Generic availability of core components.
Modest prescription growth.
Regulatory and labeling obligations.
Competition from transdermal and nonhormonal products.

What generic launch risks exist for estradiol/norgestimate?

A direct generic launch would face more commercial than legal risk. The likely launch scenario would involve low initial volume, rapid price compression, and substitution by alternative hormone therapies.

The main risks are:

An inactive or commercially unsuitable reference product.
Difficulty generating sufficient bioequivalence or comparative data for the sequential package.
Limited pharmacy demand.
Payer preference for cheaper separate components.
Physician preference for micronized progesterone or transdermal estradiol.
Low expected return on manufacturing and regulatory investment.

Manufacturing barriers are modest. The product uses established active ingredients and a conventional oral dosage form. Technical challenges could include low-dose content uniformity, stability, packaging, and reliable production of the tablet sequence. These are execution issues rather than durable intellectual-property barriers.

What licensing deals and litigation affect estradiol/norgestimate?

No material current licensing transaction or active patent litigation is publicly associated with the estradiol/norgestimate franchise. Historical rights would have followed the branded product's sponsor and any corporate transactions involving its pharmaceutical portfolio. The product's age and limited revenue reduce the probability of a new standalone licensing transaction.

There is also no biosimilar pathway. Estradiol and norgestimate are chemically synthesized small molecules, not biologics. The relevant competitive pathways are abbreviated new drug applications, product-line extensions, and therapeutic substitution.

Key Takeaways

Estradiol/norgestimate was marketed in the United States as Prefest for menopausal hormone therapy.
The product is a legacy oral combination with no meaningful current exclusivity profile.
Core ingredients are old small molecules, and no biologic or biosimilar issue exists.
The main commercial threat is therapeutic substitution, not direct patent litigation.
Transdermal estradiol, micronized progesterone, estradiol/norethindrone, and nonhormonal products have stronger current market relevance.
Public filings do not identify material standalone revenue for estradiol/norgestimate.
A generic launch would face limited legal barriers but weak commercial economics.
The product has little standalone licensing or investment value unless included in a broader women's-health portfolio.

FAQs About Estradiol/Norgestimate

Is Prefest still available in the United States?

Prefest is a historical estradiol/norgestimate product whose U.S. commercial availability has materially declined. It is not a major active branded product in the current menopause market.

Is norgestimate the same as micronized progesterone?

No. Norgestimate is a synthetic progestin. Micronized progesterone is progesterone formulated for oral administration. They are different active substances with different clinical and commercial profiles.

Can estradiol/norgestimate be replaced by separate estradiol and progesterone?

A clinician may select separate estrogen and progestogen therapy when clinically appropriate. That approach can provide dosing flexibility but is not automatically identical to the historical Prefest regimen.

Does estradiol/norgestimate have biosimilar competition?

No. Biosimilars apply to biological products. Estradiol and norgestimate are small-molecule drugs, so competition proceeds through generic-drug pathways.

Is estradiol/norgestimate commercially attractive for a generic manufacturer?

The technical development burden is likely manageable, but expected commercial returns are limited by low market demand, alternative therapies, and the absence of a strong branded price umbrella.

References

U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugsatfda
U.S. Food and Drug Administration. (n.d.). Menopausal hormone therapy information. https://www.fda.gov/consumers/womens-health-topics/menopause
Rossouw, J. E., Anderson, G. L., Prentice, R. L., LaCroix, A. Z., Kooperberg, C., Stefanick, M. L., Jackson, R. D., Beresford, S. A. A., Howard, B. V., Johnson, K. C., Kotchen, J. M., & Ockene, J. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women’s Health Initiative randomized controlled trial. JAMA, 288(3), 321-333.
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
U.S. Food and Drug Administration. (n.d.). FDA-approved drug products and regulatory exclusivity. https://www.fda.gov/drugs/development-resources/regulatory-exclusivity-drugs-annual-report-questions-and-answers

US Patents:	0
Tradenames:	2
Applicants:	2
NDAs:	2
Clinical Trials:	30
DailyMed Link:	estradiol; norgestimate at DailyMed

Estradiol; norgestimate - Generic Drug Details

What are the generic sources for estradiol; norgestimate and what is the scope of freedom to operate?

Summary for estradiol; norgestimate

Recent Clinical Trials for estradiol; norgestimate

Anatomical Therapeutic Chemical (ATC) Classes for estradiol; norgestimate

US Patents and Regulatory Information for estradiol; norgestimate

Expired US Patents for estradiol; norgestimate